Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments | ACS Applied Bio Materials
Rapid characterization of spike variants via mammalian cell surface display
Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern | EMBO reports
Rapid characterization of spike variants via mammalian cell surface display | bioRxiv
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes | Nature Communications
Carnosine improves aging‐induced cognitive impairment and brain regional neurodegeneration in relation to the neuropathological alterations in the secondary structure of amyloid beta (Aβ) - Banerjee - 2021 - Journal of Neurochemistry - Wiley Online Library
Human ACE2 Peptide-Attached Plasmonic-Magnetic Heterostructure for Magnetic Separation, Surface Enhanced Raman Spectroscopy Identification, and Inhibition of Different Variants of SARS-CoV-2 Infections | ACS Applied Bio Materials
PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma - Wang - 2020 - Cancer Medicine - Wiley Online Library
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion | Nature
Rapid characterization of spike variants via mammalian cell surface display - ScienceDirect
Guideline Therapeutics and COVID-19: living guideline
Biophysical fitness landscape of the SARS-CoV-2 Delta variant receptor binding domain | bioRxiv
Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern - eBioMedicine
Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern | EMBO reports
Human ACE2 Peptide-Attached Plasmonic-Magnetic Heterostructure for Magnetic Separation, Surface Enhanced Raman Spectroscopy Identification, and Inhibition of Different Variants of SARS-CoV-2 Infections | ACS Applied Bio Materials
Monoclonal antibody therapies against SARS-CoV-2 - The Lancet Infectious Diseases
Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2: Molecular Therapy - Methods & Clinical Development
Easy & Reliable – Biomedica´s Cytokine ELISA Kits | Biomedica
Molecular aspects of Omicron, vaccine development, and recombinant strain XE: A review - K - 2022 - Journal of Medical Virology - Wiley Online Library
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
新型コロナウイルス感染症に関する 国内外の研究開発動向について
Frontiers | Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy
ACWI ex JAPAN ex CHINA A 2022 May SAIR Constituent
Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany - The Lancet Regional Health – Europe
